Going, going... Trimeris winds down ops

Faced with a patent fight that has frustrated efforts to find a buyer, Trimeris has begun to hand back out $80 million in cash as it winds down its operations. The Trimeris board has authorized returning $50 million to shareholders by the end of the year, and analysts note that all but 10 workers have been let go. Once brimming with potential, Triangle has put its lab up for lease and spun out its R&D work.

"We believe this is consistent with the goal of returning value to investors," said Martin Mattingly, Trimeris' fourth CEO in a year. Analysts told the News & Observer that the recent moves would likely most benefit the company's large institutional investors. Biotech analyst Sharon Seiler said the company should disappear in about a year.

- check out the report from the News & Observer

Related Articles:
Trimeris' shareholder calls for sale of developer
Trimeris to axe R&D ops in '08 restructuring
Novartis sues Trimeris for patent infringement
Trimeris cuts jobs, focuses on revenue

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.